Introduction {#sec1}
============

Endoscopic endonasal surgery (EES) has been gaining popularity over the past 2 decades as an atraumatic and a reliable approach for the management of sellar, suprasellar, and anterior cranial fossa lesions. Visual field defects, headaches, ophthalmoplegia, hypopituitarism, and hormone hypersecretion are common presentations of a pituitary adenoma, one of the most common sellar lesions.[@bib1], [@bib2], [@bib3] Microsurgical transsphenoidal approaches had been the gold standard for sellar and suprasellar procedures for decades before the introduction of EES into the neurosurgical field in the mid to late 1990s.[@bib2] The sellar and suprasellar EES technique was a translation from the field of otolaryngology, where it was initially used to replace the previous "open" method of sinus surgery.[@bib3] Microscopic transsphenoidal pituitary surgery had not evolved significantly since its introduction by Harvey Cushing in 1909, until the pioneering work of Hae-Dong Jho in 1997 at the University of Pittsburgh school of medicine.[@bib4] Jho et al[@bib5] demonstrated that endoscopic transsphenoidal approaches were possible for pituitary surgery and could facilitate faster postoperative recovery compared with the gold standard microsurgical approach. EES has continued to gain favorability over conventional microsurgical transsphenoidal approaches for sellar-suprasellar lesions whatever the size and type of the tumor due to the panoramic view of the surgical field, easier mobility of surgical instruments, and better views of anatomic corners with angled lenses.[@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13]

Endoscopic surgical approaches are associated with a learning curve, and for this reason many neurosurgeons have steered clear of attempting this newer technique.[@bib11] However, current EES research has not focused on the specifics of this learning curve, the clinical and practical implications for a surgeon just beginning to practice EES, or the amount of experience required to become proficient. As well, neurosurgeons in favor of the traditional microscopic approach prefer maintaining stereoscopic vision and direct instrument visualization throughout the procedure. Initially, there were concerns regarding instrument maneuverability in EES; however, technologic advances such as the binarial endoscopic approach have resolved early concerns.[@bib14]

Li et al[@bib15] demonstrated that countries such as the United States, with high gross domestic products, tend to contribute more to the field of EES. With this in mind, it is understandable how only large, well-funded academic centers have been able to introduce EES successfully into their neurosurgery programs.[@bib15]

There is currently no research showing the adoption and success of EES in small, nonacademic community hospitals, yet a portion of patients with sellar and suprasellar lesions are seen by community neurosurgeons. In Ontario, wait times in 2018 exceeded 26 weeks for neurosurgical patients to access surgery at a university-affiliated health science center.[@bib16] ^,^ [@bib17] Knowledge regarding the feasibility of EES in smaller community hospitals may help increase access to evidence-based neurosurgical practices for patients with sellar and suprasellar lesions, especially after recent recommendations during the COVID-19 pandemic of fair allocation of medical resources among different types of hospitals.[@bib18] The purpose of this study was to demonstrate that EES can be used successfully for the treatment of sellar, suprasellar, and anterior skull base lesions in a community hospital setting, as well as to demonstrate and quantify the steep learning curve associated with EES.

Material and Methods {#sec2}
====================

STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines were used to ensure the appropriate reporting of this observational study.[@bib19]

Data Acquisition {#sec2.1}
----------------

We retrospectively reviewed the charts of 56 patients with sellar, suprasellar, and anterior skull base lesions who underwent EES between 2010 and 2018 at Windsor Regional Hospital. Demographic and surgical characteristics were reviewed including patient age, sex, clinical picture, lesion size, extent of resection (according to postoperative MRI, it was divided into gross total resection \[GTR, absence of any tumor residual\]; subtotal resection \[\<10% residual of the initial tumor size\]; and biopsy), pathology, surgical complications, and clinical outcomes.

Surgical Technique {#sec2.2}
------------------

All surgeries were performed by 1 of the 4 neurosurgeons and 1 of the 2 otolaryngologists. They achieved binostril access using a 4-handed technique. A perioperative lumbar drain was not used generally except in 2 patients who developed postoperative cerebrospinal fluid (CSF) leak. All patients received intravenous cefazolin 30 minutes before surgery and another single dose 8 hours after surgery, which is similar to previously reported regimens.[@bib20] ^,^ [@bib21] After the patient was generally anesthetized and endotracheally intubated, the area of the nose was prepped and draped in the usual sterile fashion. Next, the otolaryngologist lateralized the middle turbinates bilaterally, followed by harvesting a vascularized unilateral nasoseptal flap. In recurrent cases, the vascularized nasoseptal flap of the contralateral side of the previous approach was harvested. Depending on the location and extent of the tumor, the bony access was expanded from the sphenoid to include transclival and/or transplanum exposure (extended endonasal) as needed. In the olfactory groove meningioma patient, the tumor was accessed through a transethmoid approach. The dura over the tumor was coagulated and opened in a cruciate fashion. The tumor excision/biopsy was carried out according to the pathology of the tumor. After excision/biopsy of the tumor, adequate hemostasis was achieved, followed by reconstruction of the skull base using a simple layer of Surgicel (Ethicon, Somerville, New Jersey, USA), a layer of Tisseel (Baxter Healthcare, Deerfield, Illinois, USA); a small layer of fat graft in the sinus, followed by of Tisseel (Baxter Healthcare, Deerfield, Illinois, USA); and finally a vascularized nasoseptal flap (added only in the second half of patients). In cases of intraoperative high-flow CSF leak and extended approaches, an additional layer of inlay and onlay fascia lata graft were used. Valsalva maneuver was done to confirm no CSF leakage. Medialization of the middle turbinates were done as the final stage of the procedure.

Learning Curve {#sec2.3}
--------------

For each surgeon, the patients were divided evenly into the first and second halves. The results of the first and second halves of each surgeon and the total number of patients were compared in terms of postoperative CSF leak, meningitis, new hormonal deficit, permanent diabetes insipidus, and visual improvement. We divided the outcomes according to surgeons to show the initial outcomes of neurosurgeons who received formal training on the endoscopic transsphenoid skull base surgeries and compare them with the other general neurosurgeons.

Literature Review {#sec2.4}
-----------------

We compared our results with the recently published data discussing in detail the clinical outcomes of EES in pituitary adenoma resection (most of our patients were pituitary adenomas, and there is a paucity of studies describing the outcomes of sellar-suprasellar lesions in general) at academic centers in the past 5 years. Non-English language studies and studies describing the clinical outcome in a certain age group were excluded.

Statistical Analysis {#sec2.5}
--------------------

Continuous variables were described as a mean ± standard deviation, whereas discrete variables were described as frequency (% of total). Continuous and discrete variables were analyzed via the Exact Fischer test and chi-square test. *P* value \<0.05 was considered statistically significant. Data were analyzed using SPSS version 16.0 (IBM Inc).

Results {#sec3}
=======

Preoperative Characteristics {#sec3.1}
----------------------------

In our retrospective observational study, there were 56 patients, with male predominance (53.6%) and a mean age of 54.9 ± 13.7 (range, 27--82) years. The mean follow-up duration was 47.5 ± 25.8 months. All patients were undergoing a first-time resection of their lesion except there were 5 patients (8.9%) who had recurrent tumors treated with prior surgery (4 with previous microscopic transnasal transsphenoidal and 1 with a previous transcranial resection). Lesions included 45 pituitary adenomas (36 nonfunctioning, 3 prolactinomas, 3 gonadotrophin releasing hormone secreting, 2 adrenocorticotropic hormone secreting, and 1 growth hormone secreting), 5 meningiomas (4 tuberculum sellae and 1 olfactory groove), 3 metastatic lesions, 1 craniopharyngioma, 1 Rathke cyst, and 1 mucocele ([Table 1](#tbl1){ref-type="table"} ). The mean size of the lesions was 2.76 ± 1.06 cm in the craniocaudal dimension, 2.15 ± 0.82 cm in the anteroposterior dimension, and 2.2 ± 0.81 cm in the transverse dimension ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} ). The patients with Knosp grades 3 and 4 were 35.5% of the pituitary adenoma patients. The tumor location, extension, and neurovascular relations of each case are reported in [Table S1](#tblS1){ref-type="table"}.Table 1Preoperative CharacteristicsParameterValueAge (years) Mean54.9 Range27--82 Standard deviation13.7Sex Male30 (53.6) Female26 (46.4)Recurrent tumor5 (8.9)Lesion type Pituitary adenomas45 (80.4) Nonfunctioning36 (64.3) Prolactinoma3 (5.4) Growth hormone secreting1 (1.8) GnRH secreting3 (5.4) ACTH secreting2 (3.8) Meningioma5 (8.9) Tuberculum sellae4 (7.1) Olfactory groove1 (1.8) Metastasis3 (5.4) Craniopharyngioma1 (1.8) Mucocele1 (1.8)[^1][^2]Figure 1T1-weighted magnetic resonance imaging of the head with contrast of a 62-year-old female patient who presented with loss of smell sensation. (**A**) Preoperative axial view. (**B**) Preoperative coronal view. (**C**) Postoperative axial view. (**D**) Postoperative coronal view.Figure 2T1-weighted magnetic resonance imaging of the sella with contrast of a 68-year-old female patient who presented with bitemporal hemianopia. (**A**) Preoperative coronal view. (**B**) Preoperative sagittal view. (**C**) Postoperative coronal view. (**D**) Postoperative sagittal view.

Clinical Presentation {#sec3.2}
---------------------

The clinical presentation of patients in our study was heterogeneous. Patients presented with, in order of prevalence, headache, hormonal deficit, visual deficit, cranial nerve deficit, diplopia, and pituitary apoplexy. The majority of patients (42/56, 75%) presented with headache. A large proportion also presented with some form of hormonal deficit (31/56, 57.1%). These included panhypopituitarism, hypothyroidism, hypogonadism, hypoadrenalism, and hyperprolactinemia. Some patients experienced more than 1 hormonal deficit. The GnRH-secreting pituitary adenomas presented with mass effect rather than endocrine symptoms. Most (31 of 56) patients (55.4%) presented with a visual deficit. The most common visual deficit was bitemporal hemianopia (14/31, 45% of patients with visual field defects). Ten patients had cranial nerve deficits (17.9%), most commonly a third nerve palsy. Nine (16.1%) of 56 patients experienced diplopia. Eight (14.3%) of 56 patients had pituitary apoplexy. The majority of patients had a normal mental status; however, 12.5% presented with a disturbed level of consciousness ([Table 2](#tbl2){ref-type="table"} ).Table 2Clinical PresentationParameterValueHeadache42/56 (75%)Hormonal deficit32 (57.1%) Hypothyroidism12/32 (37.5%) Hypogonadism11/32 (34.4%) Panhypopituitarism6/32 (18.8%) Hyperprolactinemia5/32 (15.6%) Hypoadrenalism4/32 (12.5%) Cushing disease3/32 (9.4%)Visual field deficit31/56 (55.4%) Bitemporal hemianopia14/31 (45.2%) Other deficits17/31 (54.8%)Cranial nerve deficit10/56 (17.9%) Third nerve palsy3/10 (33.3%)Diplopia9/56 (16.1%)Pituitary apoplexy8/56 (14.3%)Disturbed level of consciousness7/56 (12.5%)[^3]

Perioperative Outcomes {#sec3.3}
----------------------

Standard EES surgery was done in 49 (87.5%) patients, and extended EES was done in 7 (12.5%) patients. GTR was achieved in 32 (57.1%) patients, subtotal excision in 21 (37.5%) patients, and decompression and biopsy in three (5.4%) patients. The reasons for not achieving GTR were cavernous sinus invasion in 13 (23.2%) patients, surgeon\'s inexperience in 5 (8.9%) patients, and optic apparatus invasion/adherence in 2 (3.6%) patients. Finally, the initial aim of surgery was not GTR in four (7.1%) patients. None of the patients received adjuvant radiotherapy except the 3 metastatic lesions. There was no reported intraoperative complication. Postoperative vision normalized or improved in 27 (86.1%) patients or remained stable in 4 (13.9%) patients. There was no worsening of visual symptoms. Recovery of a preexisting hormonal deficit occurred in 13 (23.2%) patients, and a new hormonal deficit requiring hormonal replacement occurred in 9 (16.1%) patients. The mean hospital stay was 6.1 ± 4.9 days. Postoperative complications included postoperative CSF leak in 8 (14.3%) patients (3 \[5.4%\] of them were operated on by extended EES). Four (7.1%) patients had meningitis, diabetes insipidus was present in 19 (33.9%) patients (6 permanent and 13 transient), and postoperative intracranial hematomas required evacuation in 2 (3.6%) patients. Of the 8 patients who suffered a CSF leak, 3 resolved nonoperatively. One resolved by bed rest only, and 2 resolved with a lumbar drain. Five patients with postoperative CSF leak required surgical repair with Surgicel (Ethicon, Somerville, New Jersey, USA), Tisseel (Baxter Healthcare, Deerfield, Illinois, USA), fat graft, and fascia lata graft. Two of these patients required only 1 repair attempt, 1 required 2 attempts, and 2 required 3 attempts to treat the CSF leak. There is no reported mortality during the first 30 days post surgery. Lesion progression or recurrence requiring redo surgery occurred in 5 (8.9%) patients; all of them were nonfunctioning pituitary adenomas ([Table 3](#tbl3){ref-type="table"} ). We compared our results with the recently published data discussing in detail the clinical outcomes of EES in pituitary adenoma resection at academic centers in the past 5 years ([Table 4](#tbl4){ref-type="table"} ).Table 3Perioperative OutcomesParameterValueExcision Gross total excision31 (55.4) Subtotal excision22 (39.3) Decompression and biopsy3 (5.4)Vision Normal to improved27 (86.1) Remained stable4 (13.9) Worsened0Complications New hormone deficiency9 (16.1) Postoperative CSF leak8 (14.3) Meningitis4 (7.1) Diabetes insipidus Transient13 (23.2) Permanent6 (10.7) Hematoma and evacuation2 (3.6)Vascular injury0Nasal complications0Other complications0Lesion progression or recurrence5 (8.9)[^4][^5]Table 4Comparison of Demographics, Postoperative Results, and Complications of Endoscopic Endonasal Studies in the Past 5 YearsStudyAge (Years)Sex (% male)Macroadenoma (%)GTRVision Normalized or Improved (%)Vision Worsened (%)New Hormonal Deficit (%)Postoperative CSF Leak (%)Postoperative Hematoma (%)Meningitis (%)Permanent DI (%)30-day Mortality (%)RecurrenceChabot et al., 2015[@bib22]56.364.11008579012.810.3------7.700Marenco et al., 2015[@bib23]72.44410065.470.80164---4---421.4Wang et al., 2015[@bib24]40.344.37991.7920.431.30.60.691.030.69------Akin et al., 2016[@bib25]35.546.586.6-100018.22.1-2.80---3.5Guo-Dong et al., 2016[@bib26]43.459-73.1750313010---Jang et al., 2016[@bib27]48.443.870.469.2------1.21.80.60.60.90.3---Jones et al., 2016[@bib28]62.396---80100004000------Magro et al., 2016[@bib29]57571005986.62.413.72.723.36.20.7---Qureshi et al., 2016[@bib30]52.655.196.193.696.5010.81.3------2.6------Yildirim et al., 2016[@bib31]48.5551009039.107.51.8------1.30.6---Zhan et al., 2016[@bib32]36.557.862.286.792.7011.14.4---000---Beltrame et al., 2017[@bib33]48.54478.66073.83.212.12.11.41.43.20.72.9Gondim et al., 2017[@bib34]54.969.210079.574.1------0---0**5.10**---Linsler et al., 2017[@bib35]55.541.481.488---0110001.406Thawani et al., 2017[@bib36]55.751.210029.6---1.48---10.3---14.41---Zhang et al., 2017[@bib37]---53.310067.237.20.73.51.5---2.90---16.7Zoli et al., 2017[@bib38]52.462.71008085.50201.3-05.3-4Hajdari et al., 2018[@bib39]57.457.185.373.458.61.1711.88.20.62.3---------López-García et al., 2018[@bib40]54478977912.2901.21.23------Taghvaei et al., 2018[@bib41]39.447.176.589.710004.42.9---05.90---Castano-Leon et al., 2019[@bib42]524082.563.971.41.0318.62.12.14.13.10.76.2Pablo et al., 2019[@bib43]------78.660231.03122.11.42.12.10.77Our study54.953.694.655.487.1016.18.93.67.110.708.9[^6]

Learning Curve {#sec3.4}
--------------

There was a higher rate of complications in earlier cases. When comparing the first half of operations to the latter half, the combined 4 neurosurgeons found a statistically significant (*P* \< 0.05) decrease in postoperative CSF leak from 7/28 (25%) to 1/28 (3.6%) cases ([Figure 3A](#fig3){ref-type="fig"} ). Combined rates of postoperative meningitis decreased from 3/28 (10.7%) to 1/28 (3.6%) cases (*P* = 0.3) (see [Figure 3B](#fig3){ref-type="fig"}). Combined rates of new hormonal deficits decreased from 6/28 (21.4%) to 3/28 (10.7%) (*P* = 0.28) (see [Figure 3C](#fig3){ref-type="fig"}). Combined rates of permanent postoperative diabetes insipidus decreased from 5/28 (17.9%) to 1/28 (3.6%) cases (*P* = 0.08) (see [Figure 3D](#fig3){ref-type="fig"}). As well, combined rates of visual improvement increased from 13/17 (76.5%) to 17/18 (94.4%) cases (*P* = 0.13) when comparing the early half of cases to the latter half (see [Figure 3E](#fig3){ref-type="fig"}). The least rate of complications was among the only neurosurgeon who did a formal endoscopic skull base fellowship ([Table 5](#tbl5){ref-type="table"} ).Figure 3Postoperative clinical outcomes for each half of sample population, by surgeon showing the learning curve. (**A**) Percentage of postoperative cerebrospinal fluid leak. (**B**) Percentage of meningitis. (**C**) Percentage of postoperative new hormonal deficit. (**D**) Percentage of permanent diabetes insipidus. (**E**) Percentage of postoperative visual improvement.Table 5Statistical Significance of Postoperative Clinical Outcomes for Each Half of Sample Population, by SurgeonParameterFirst HalfSecond Half*P* ValuePostoperative CSF leak: Surgeon A2/5 (40)1/5 (20)0.49 Surgeon B3/11 (27.3)0/10 (0)0.07 Surgeon C0/6 (0)0/6 (0)1 Surgeon D2/6 (33.3)0/7 (0)0.1 Total7/28 (25)1/28 (3.6)**\<0.05**Meningitis Surgeon A2/5 (40)1/5 (20)0.49 Surgeon B1/11 (9.1)0/10 (0)0.33 Surgeon C0/6 (0)0/6 (0)1 Surgeon D0/6 (0)0/7 (0)1 Total3/28 (10.7)1/28 (3.6)0.3New hormonal deficits Surgeon A3/5 (60)1/5 (20)0.2 Surgeon B2/11 (18.2)1/10 (10)0.59 Surgeon C0/6 (0)1/6 (16.7)0.3 Surgeon D1/6 (16.7)0/7 (0)0.26 Total6/28 (21.4)3/28 (10.7)0.28Permanent diabetes insipidus Surgeon A2/5 (40)0/5 (0)0.11 Surgeon B2/11 (18.2)0/10 (0)0.16 Surgeon C1/6 (16.7)1/6 (16.7)1 Surgeon D0/6 (0)0/7 (0)1 Total5/28 (17.9)1/28 (3.6)0.08Vision improvement Surgeon A1/1 (100)4/4 (100)1 Surgeon B7/9 (77.8)7/7 (100)0.18 Surgeon C4/4 (100)2/3 (66.7)0.21 Surgeon D1/3 (33.3)4/4 (100)0.05 Total13/17 (76.5)17/18 (94.4)0.13[^7][^8]

Discussion {#sec4}
==========

There is a growing trend toward fully endoscopic endonasal transsphenoidal surgery. Many studies show a similar if not greater efficacy of EES compared with the gold standard microsurgical techniques.[@bib26] ^,^ [@bib42] ^,^ [@bib44] This is the first study to look for the outcomes of patients undergoing endoscopic transnasal sellar, suprasellar, and anterior cranial fossa lesion excisions in a community hospital setting. It has also been demonstrated that the transition to EES is hindered by its learning curve, although the details of this learning curve and its clinical implications have not been studied in detail.[@bib45] Given the prevalence of sellar and suprasellar lesions, as well as the growing evidence for the efficacy of endoscopic endonasal transsphenoidal surgery, understanding the dynamics of the learning curve, especially in the setting of a community hospital, may help increase adoption, surgical proficiency, and improve outcomes in the management of patients with these lesions in the future in all hospital settings (academic centers, community hospitals, and developing country hospitals). Other supportive specialties, such as neurointervention to back up any intraoperative vascular complications and neuroendocrine for managing any endocrine manifestations perioperatively should be present.

Extent of Resection {#sec4.1}
-------------------

It is difficult to evaluate or compare the extent of resection when discussing the many different types of sellar and suprasellar lesions that may be approached and resected through endoscopic endonasal surgery. Certain lesions require an attempt for GTR, while others, such as metastatic lesions, have high levels of success when combined with adjuvant therapy. Definitions of GTR, subtotal resection, decompression, and/or biopsy are unique and can vary for each study. In a review of 16 studies of giant adenomas, Komotar et al[@bib46] noted the microscopic transsphenoidal cohort had a lower rate of total resection and worse visual outcome than the endoscopic group. Pituitary adenomas are the most frequently studied and managed endoscopically. A 2018 metanalysis of 50 studies by Almutairi et al[@bib47] demonstrated a GTR rate for pituitary adenomas of 74%. For tumors invading the cavernous sinus, many authors noted a higher resection rate with an endoscope than a microscope, indicating the advantage of the panoramic and angled views of the medial wall of the cavernous sinus provided by endoscopes. In addition, endoscopic endonasal surgery has been reported to be a valid option for resection in recurrent adenomas.[@bib48] Graffeo et al[@bib49] demonstrated in their metanalysis that current GTR rates are 89.7% for olfactory groove meningiomas, 79.9% for tubercula sella meningiomas, 59% for craniopharyngiomas, and 58.8% for clival chordomas. Our series showed that GTR was achieved in 62.2% of pituitary adenomas, 50% of tuberculum sellae meningiomas, olfactory groove meningioma and mucocele patient, subtotal resection of the tumor in the craniopharyngioma patient, and decompression and biopsy of the tumors in all metastasis patients. The main reason for not achieving GTR in our series was the cavernous sinus invasion (23.1%). Due to the paucity of cases of olfactory groove meningiomas, metastasis, craniopharyngioma, mucocele, and Rathke cyst, we could not compare our results with the literature for such pathologies.

Perioperative Outcomes {#sec4.2}
----------------------

Visual and postoperative outcomes in our study were consistent with the results shown in other studies.[@bib24] ^,^ [@bib33] ^,^ [@bib40] ^,^ [@bib42] ^,^ [@bib43] ^,^ [@bib50] Of patients experiencing visual issues at the time of diagnosis, 86.1% of patients had vision improvement and only 13.9% had no change in vision. No patients had a worsening vision. Other studies have reported rates of vision improvement from as low as 23% to as high as 100%.[@bib22], [@bib23], [@bib24], [@bib25], [@bib26] ^,^ [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34] ^,^ [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43] ^,^ [@bib50] In our study, no patients had worsened vision after surgery. This is consistent with results found by other researchers who generally saw a very low rate of worsened visual deficits after surgery, on the order of 0%--3.2%.[@bib22], [@bib23], [@bib24], [@bib25], [@bib26] ^,^ [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33] ^,^ [@bib35], [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43] ^,^ [@bib50]

The rate of recovery from hormonal deficits in our study is greater than that found by other researchers. Most of our patients (83.9%) showed stable or improved hormonal deficits. Pablo et al[@bib43] and Castano-Leon[@bib42] found that hormonal deficits were stable or improved in 76.9% and 75.3% of patients, respectively. However, our rate of new deficits postoperatively seems to be in line with that of other researchers, at 16.1%. Rates of new deficits in other studies have ranged from 0% to 20%.[@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33] ^,^ [@bib35] ^,^ [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43] ^,^ [@bib50], [@bib51], [@bib52], [@bib53], [@bib54]

Perioperative complications that we analyzed include the rates of hematoma requiring evacuation, diabetes insipidus, CSF leak, and meningitis. Our patients experienced a similar rate of postoperative hematoma when compared with previous studies described in the literature. In our literature review, the rate of this complication ranged from 0% to 3%.[@bib24] ^,^ [@bib26], [@bib27], [@bib28], [@bib29] ^,^ [@bib33] ^,^ [@bib35] ^,^ [@bib39] ^,^ [@bib40] ^,^ [@bib42] ^,^ [@bib43] Two (3.6%) of our patients experienced this complication and required surgical evacuation of the hematoma. We did have a high rate of permanent diabetes insipidus postoperatively. Six (10.7%) of our patients experienced this complication, whereas the existing literature estimates this complication occurring in 0%--7.7% of cases.[@bib22] ^,^ [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38] ^,^ [@bib40], [@bib41], [@bib42], [@bib43] ^,^ [@bib50]

In terms of the other postoperative complications, our study showed increased rates of postoperative CSF leak and meningitis. Among our patients, 14.3% experienced postoperative CSF leak. In previous studies, the prevalence of postoperative CSF leak ranged from 0%-10.3%.[@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43] ^,^ [@bib50] ^,^ [@bib55] Of these 8 patients, 3 resolved nonoperatively (1 with bed rest only and 2 with a lumbar drain). Five required surgical repair using Surgicel (Ethicon, Somerville, New Jersey, USA), Tisseel (Baxter Healthcare, Deerfield, Illinois, USA), fat graft, fascia lata graft, and vascularized nasoseptal flap. Two patients required only 1 repair, 1 patient required 2 repair attempts, and 2 patients required 3 attempts to successfully treat the CSF leak. Out of the 7 patients who were operated on by extended EES, 3 (42.9%) of them developed postoperative CSF leak. This constitutes 37.5% of the patients who developed postoperative CSF leak. However, the CSF leak rate has significantly dropped from 25% to 3.6% (*P* \< 0.05) after using vascularized nasoseptal flaps and proper skull base reconstruction, especially in extended EES cases, and the results were comparable with similar studies.[@bib23] ^,^ [@bib25] ^,^ [@bib28] ^,^ [@bib29] ^,^ [@bib33] ^,^ [@bib41], [@bib42], [@bib43] ^,^ [@bib56] ^,^ [@bib57] Of our patients, 7.1% experienced meningitis, whereas the prevalence of this in other studies generally ranged from 0%--4.1%. The 30-day mortality rate was 0%, and in the other studies it ranged from 0%--4%.[@bib22] ^,^ [@bib23] ^,^ [@bib26] ^,^ [@bib27] ^,^ [@bib29] ^,^ [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36] ^,^ [@bib41], [@bib42], [@bib43]

Fewer studies have assessed the length of stay after EES; however, our patients\' length of stay appears to be on the high end of a range from 3--6 days.[@bib33] ^,^ [@bib42] ^,^ [@bib55] Our patients remained in the hospital for 6.1 ± 4.9 days. This may have been due to the relative unfamiliarity of our center with the procedure; the staff therefore may have wanted to observe patients for a longer duration of time. Finally, our recurrence rate was 8.9%, which is within the reported range from 2%--21.4%.[@bib22] ^,^ [@bib23] ^,^ [@bib25] ^,^ [@bib33] ^,^ [@bib35] ^,^ [@bib37] ^,^ [@bib38] ^,^ [@bib42] ^,^ [@bib43]

Overall, our outcome results and complication rates were relatively higher than those of researchers in academic centers. However, this postoperative complication rate showed a decrease from the first to second half of cases. Therefore this number is likely influenced by the fact that such a large proportion of our cases represented our community neurosurgeons beginning to perform these types of surgeries.

Learning Curve {#sec4.3}
--------------

Our study showed that rates of postoperative CSF leak, meningitis, new hormonal deficits, and permanent diabetes insipidus decreased from the first group of surgeries to the second group when all surgeons were analyzed together. However, only the incidence of postoperative CSF leak decreased significantly (7/28 in the first patient group, 1/28 in the second patient group, *P* \< 0.05). This significant decrease is attributed to the use of vascularized nasoseptal flap in the second half of patients. Our small sample size may be the reason that the other complications did not reach statistical significance. However, this is consistent with other studies that have also not shown statistical significance for a decrease in complications.[@bib30] ^,^ [@bib58] ^,^ [@bib59] One study has even shown an increase in the complication rate, which was hypothesized to be due to increased surgeon confidence and aggressiveness in attempting GTR as surgeons gained experience with the procedure.[@bib51] Despite this, the decrease in complication rate is certainly clinically significant and reduces the burden on surgeons and patients when reintervention is necessary.

In terms of improvement in outcome, the visual improvement did better from the first half of the case series (13 of 17 patients) to the second (17 of 18 patients); however, this was not statistically significant (*P* = 0.13). When we divided the outcomes according to surgeons, we found that the initial outcomes of the neurosurgeon who received formal training on the endoscopic transsphenoid skull base surgeries were better than the other general neurosurgeons.

The rapid decrease in complications from the first to second series of cases, while not statistically significant, shows that the learning curve for EES is steep. This means that once our surgeons gained experience with the procedure, the complication rates decreased dramatically.

Challenges and Limitations {#sec4.4}
--------------------------

This study has several limitations. Firstly, this is a retrospective study with an extremely heterogeneous patient population in regard to pathologic diagnosis encompassing a variety of pituitary adenomas, tuberculum sellae and olfactory groove meningiomas, metastasis, craniopharyngioma, Rathke cyst, and a mucocele. The patient population was small with 56 cases, with each of surgeons A, B, C, and D completing 10, 21, 12, and 13 operations, respectively. All of these challenges were overcome. We think that there is a better outcome in terms of patient care when there is interspecialty teamwork among neurosurgeons, otolaryngologists, endocrinologists, ophthalmologist/optometrist, and neurointerventionist. One challenge in regards to initiating the EES, especially in a community hospital setting where EES is relatively new, is that neurosurgeons do not have an abundance of previous experience with endoscopic nasal anatomy. Therefore if there were any intraoperative complications regarding nasal anatomy, an otolaryngologist would be called into the operating room without any prior notice. This was going to lead to increased levels of frustration, especially between neurosurgeons and otolaryngologists. The obvious solution was to increase teamwork and collaboration between the specialties. In this regard, 2 neurosurgeons and 2 otolaryngologists attended several cadaveric courses to learn this new technique together. Only 2 of the local otolaryngologists agreed to participate in the EES operations. This presented another challenge. If any of the postoperative patients presented to the emergency department after discharge, none of the uninvolved otolaryngologists would consider seeing these patients. The otolaryngologists had to better intercommunicate so that they were all comfortable seeing patients post EES presenting with purely nasal problems such as epistaxis. The neuronavigation billing code for remuneration also needed to be alternated between the neurosurgeons and otolaryngologists to better develop the working relationship between the specialties. Other challenges that arose included administrative issues, such as a lack of funding for and a shortage of nasal instrument sets; the logistics of arranging an otolaryngologist and neurosurgeon to be available at the same time; and education of the neurosurgical operating room nursing staff in regards to otolaryngologic procedures. We overcame all these challenges.

The future direction is to train more neurosurgeons in EES techniques. Then it will be more feasible to perform these cases in a community hospital setting. In our case series, only 1 surgeon (D) had a previous fellowship training in endoscopic transsphenoidal surgery with better outcomes than other neurosurgeons. We hope that new trainees will be trained and confident in performing these surgeries in community hospitals.

Conclusion {#sec5}
==========

Despite the fact that our overall complications are higher than those in the reported literature, the outcomes of the second half of patients after the surgeons gained experience were similar to those in academic centers. However, complex cases (e.g., anterior cranial fossa lesions and craniopharyngiomas) should be referred to an experienced surgeon, such as a well-trained endoscopic skull base surgeon in the same center or in an academic center. The learning curve for EES is steep and improves greatly and quickly with adequate practice. So, endoscopic endonasal resection of sellar, suprasellar, and anterior skull base lesions is safe, minimally invasive, and efficient in a community hospital setting, provided the presence of a multidisciplinary team such as neurointervention and neuroendocrinology. Extent of resection, visual, and postoperative outcomes after gaining experience are similar to those reported in larger academic centers. In the future, as time will allow for the progression of endoscopy instruments and increased surgeon experience, this approach should become first line for the treatment of sellar and suprasellar lesions in hospitals of all settings (academic centers, community hospitals, and developing country hospitals).
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Table S1Tumor Type, Location, Extension, Neurovascular Relation, Type of Surgery, and Extent of Resection of 56 PatientsCase NumberTumor TypeLocationExtensionOptic ChiasmVascular RelationSurgeryExtent of Resection1Pituitary adenoma (GnRH)Sellar-suprasellarBilateral cavernous sinusCompressedBilateral mass effect on carotidStandardGTR2ProlactinomaSellar---------StandardGTR3Nonfunctioning pituitary adenomaSellar-suprasellarBilateral cavernous sinusInvasionRt. encased\
Lt. mass effectStandardGTR4Nonfunctioning pituitary adenomaSellar, suprasellar, infrasellarBilateral cavernous sinusCompressedRt. encased\
Lt. mass effectStandardGTR5Nonfunctioning pituitary adenomaSellar-suprasellarRight cavernous sinusCompressedRt. encasedStandardGTR6Nonfunctioning pituitary adenomaSellar---------StandardGTR7Olfactory groove meningiomaOlfactory groove---------ExtendedGTR8Tuberculum sellae meningiomaSuprasellar---------ExtendedGTR9Nonfunctioning pituitary adenomaSellar-suprasellarBilateral cavernous sinusCompressedBilaterally around the carotidStandardGTR10Nonfunctioning pituitary adenomaSellar-suprasellar---Compressed---StandardGTR11Pituitary adenoma (GnRH)Sellar-suprasellarBilateral cavernous sinusCompressedBilaterally around the carotidStandardGTR12Pituitary adenoma (ACTH)Sellar---------StandardGTR13Nonfunctioning pituitary adenomaSellar-Suprasellar---Compressed---StandardGTR14Nonfunctioning pituitary adenomaSellar-SuprasellarBilateral cavernous sinus, supraclinoidCompressedBilaterally around the carotidStandardGTR15Pituitary adenoma (ACTH)Sellar-suprasellarBilateral cavernous sinus, left temporal lobe---Bilaterally around the carotidStandardGTR16Nonfunctioning pituitary adenomaSellar-SuprasellarBilateral cavernous Sinus---Bilateral mass effect on carotidStandardGTR17Nonfunctioning pituitary adenomaSellar-suprasellarLeft cavernous sinusCompressedLt. encasedStandardGTR18ProlactinomaSellar---------StandardSTR19MetastasisSuprasellar---------StandardDecompression and biopsy20Tuberculum sellae meningiomaSellar-suprasellar---Compressed---StandardSTR21Tuberculum sellae meningiomaSellar-suprasellarFrontal lobe------ExtendedGTR22MucoceleSellar---------StandardGTR23Nonfunctioning pituitary adenomaSellar-suprasellarBilateral cavernous sinusCompressedRt. encased and left around the carotid but not totally encasedStandardSTR24Pituitary adenoma (GnRH)Sellar-suprasellarBilateral cavernous sinusCompressedBilaterally around the carotidStandardSTR25Nonfunctioning pituitary adenomaSellar-suprasellarLeft cavernous sinusCompressedLt, around the carotidStandardSTR26Nonfunctioning pituitary adenomaSellar-suprasellarBilateral cavernous sinusCompressedBilaterally around the carotidStandardSTR27Rathke cystSellar-suprasellar---Compressed---StandardSTR28Nonfunctioning pituitary adenomaSellar-suprasellarRt. cavernous sinusCompressedRt. around the carotidStandardSTR29Nonfunctioning pituitary adenomaSellar-suprasellarBilateral cavernous sinusCompressedBilaterally around the carotidStandardSTR30Nonfunctioning pituitary adenomaSellar-Suprasellar---Compressed---StandardSTR31Nonfunctioning pituitary adenomaSellar-suprasellarRt. cavernous sinusCompressedRt. encasedStandardSTR32Tuberculum sellae meningiomaSellar-suprasellarHypothalamus, orbital apex, left supraclinoid, frontal lobeCompressedLt. supraclinoid carotid artery encasedExtendedSTR33Nonfunctioning pituitary adenomaSellar---------StandardGTR34Nonfunctioning pituitary adenomaSellar-suprasellar---Compressed---StandardGTR35Nonfunctioning pituitary adenomaSellar---------StandardGTR36Nonfunctioning pituitary adenomaSellar-suprasellar---Compressed---StandardGTR37Nonfunctioning pituitary adenomaSellar-suprasellar---Compressed---StandardSTR38Nonfunctioning pituitary adenomaSellar-suprasellarBilateral cavernous sinusCompressedBilaterally around the carotidStandardSTR39Nonfunctioning pituitary adenomaSellar-suprasellar---Compressed---StandardSTR40ProlactinomaSellar-suprasellarBilateral cavernous sinus, frontal lobeCompressedBilaterally around the carotidStandardSTR41Nonfunctioning pituitary adenomaSellar-suprasellar---Compressed---StandardSTR42Pituitary adenoma (GH)Sellar---------StandardGTR43Nonfunctioning pituitary adenomaSellar-suprasellarBilateral cavernous sinusCompressedBilateral encasedStandardSTR44Nonfunctioning pituitary adenomaSellar-suprasellar---Compressed---StandardGTR45Nonfunctioning pituitary adenomaSellar---------StandardGTR46Nonfunctioning pituitary adenomaSellar---------StandardGTR47Nonfunctioning pituitary adenomaSellar, suprasellar, infrasellarBilateral cavernous sinus, hypothalamus, bilateral temporal lobesCompressedLt. encased\
Rt. mass effectExtendedSTR48Nonfunctioning pituitary adenomaSellar-suprasellarBilateral cavernous SinusCompressedBilaterally around the carotidStandardGTR49Nonfunctioning pituitary adenomaSellar-suprasellarBilateral cavernous sinusCompressedBilaterally mass effectStandardGTR50Nonfunctioning pituitary adenomaSellar-Suprasellar---Compressed---StandardGTR51Nonfunctioning pituitary adenomaSellar-suprasellarBilateral cavernous sinus, frontal lobeCompressedBilaterally around the carotidStandardGTR52Nonfunctioning pituitary adenomaSellar---------StandardGTR53Nonfunctioning pituitary adenomaSellar, clival, infrasellarBilateral cavernous sinus, Rt. Meckel cave and prepontine cisternInvasionEncased bilateralExtendedSTR54MetastasisSellar, infrasellarBilateral cavernous sinus, Meckel cave---Bilaterally around the carotidStandardDecompression and biopsy55MetastasisSellar-suprasellarBilateral cavernous sinus, hypothalamusCompressedBilaterally around the carotidStandardDecompression and biopsy56CraniopharyngiomaSellar-suprasellarHypothalamusInvasion---ExtendedSTR[^9][^10]
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[^1]: All values are number of patients (%) unless stated otherwise.

[^2]: GnRH, gonadotropin releasing hormone; ACTH, adrenocorticotropic hormone.

[^3]: All values are number of patients (%) unless stated otherwise.

[^4]: All values are number of patients (%) unless stated otherwise.

[^5]: CSF, cerebrospinal fluid.

[^6]: DI, diabetes insipidus.

[^7]: *P* value indicates statistically significant.

[^8]: CSF, cerebrospinal fluid.

[^9]: All values are number of affected patients/total number of patients (%).

[^10]: GnRH, gonadotropin releasing hormone; GTR, gross total resection; ACTH, adrenocorticotropic hormone; STR, subtotal resection; GH, growth hormone.
